Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Physicians who Treat Uveitis (US)(?)

Council Members in this Study Group: 38

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Sanjay Rao, MD, Medical Director, Lakeside Eye ClinicSanjay Rao, MD
Medical Director
Lakeside Eye Clinic

Sanjay Rao, MD, is the Medical Director and Director of Cornea and Refractive Surgery at the Lakeside Eye Clinic in Chicago. He was previously the Director of Cornea and Refractive Surgery at the University of Chicago. He has clinical expertise in diseases of the cornea and is a high volume cataract,...

Barry Schechter, MD, Director of Corneal and External Diseases, Florida Eye Microsurgical Institute, Inc. Barry Schechter, MD
Director of Corneal and External Diseases
Florida Eye Microsurgical Institute, Inc.

Barry Schechter, MD, is the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute. Dr. Schechter's practice involves diseases of the ocular surface including dry eyes, allergies, infection; the latest in corneal, refractive, and cataract surgery, and glaucoma....

Eric Donnenfeld, MD, Co-Chairman of Cornea, Nassau University Medical CenterEric Donnenfeld, MD
Co-Chairman of Cornea
Nassau University Medical Center

Eric Donnenfeld, MD, is a Clinical Professor of Ophthalmology at New York University and Trustee at Dartmouth Medical School. He is Co-Chairman of Cornea at Nassau University Medical Center. He is also the Surgical Director of Lions Eye Bank for Long Island, the National Medical Director for TLC Laser...

Anne Fung, MD
Ophthalmologist
Pacific Eye Associates

Anne Fung, MD, is an Ophthalmologist specializing in Medical Retina at California Pacific Medical Center and Pacific Eye Associates in San Francisco. She has expertise in macular degeneration and has worked primarily with medical therapies for neovascular macular degeneration including Lucentis and...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
By Barry Schechter, MD, Director of Corneal and External Diseases, Florida Eye Microsurgical Institute, Inc.
Analysis of: Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com

With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.

The market for eye drops for the treatment of open angle glaucoma is huge. Profit potential for pharmaceutical companies, however, is limited by the time period that they are afforded patent protection. Combigan, the just approved brimonidine/timolol combination therapy, affords Allergan new patent...

Alacrity Biosciences has completed a Phase 2 clinical trial of ALTY-1501, an eye drop for the treatment of dry eye. Dry eye (or keratoconjunctivitis sicca (KCS) affects more than 10% of the US population and its incidence is increasing as baby boomers become senior citizens. Although the small...

Analysis of: Maker Seeks to Restrict Cancer Drug Used on Eye | www.nytimes.com

       Genentech has had first year revenues of $800 million from its drug Lucentis, which is used intravitreaaly to treat macular degeneration on label and some other conditions off label.   Although this amount of sales places Lucentis well within the blockbuster...

Inspire Pharmaceuticals' founding concept is based upon P2Y2 receptor agonist technology, now approaching fruition with groundbreaking cystic fibrosis (CF) clinicals.  Well tolerated three times daily nebulizer therapy with denufosol for young CF patients promises improved pulmonary function,...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Partner
  • Owner
  • President
  • Physician - Division Head
  • Optometrist

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

Analytics


Generated at 2009-01-08T19:00:17.880